Focal segmental glomerulosclerosis historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
===Discovery===
===Discovery===
*Focal segmental glomerulosclerosis (FSGS) was first discovered by a Theodor Fahr, a German pathologist, in 1925, he referred to it as "lipoid nephrosis with degeneration", showing a clear association to minimal change disease.<ref>{{cite book | last = Fahr |first = T | authorlink = |coauthors =  | title = Pathologische anatomie des morbus brightii. In: Fahr T, Gruber GB, Koch M, et al. eds. Harnorgane Männliche Geschlechtsorgane.| publisher = Springer |date = 1925 | location = Vienna| pages = 156-472 | url = | doi = | id = | isbn = }}</ref>
*Focal segmental glomerulosclerosis (FSGS) was first discovered by a Theodor Fahr, a German pathologist, in 1925, he referred to it as "lipoid nephrosis with degeneration", showing a clear association to minimal change disease.<ref>{{cite book | last = Fahr |first = T | authorlink = |coauthors =  | title = Pathologische anatomie des morbus brightii. In: Fahr T, Gruber GB, Koch M, et al. eds. Harnorgane Männliche Geschlechtsorgane.| publisher = Springer |date = 1925 | location = Vienna| pages = 156-472 | url = | doi = | id = | isbn = }}</ref>
*In 1957, FSGS was then described by Dr. Arnold Rich, a pathologist at Johns Hopkins University<ref name="pmid13426687">{{cite journal| author=RICH AR| title=A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. | journal=Bull Johns Hopkins Hosp | year= 1957 | volume= 100 | issue= 4 | pages= 173-86 | pmid=13426687 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13426687  }} </ref>
*In 1957, FSGS was then described by Dr. Arnold Rich, a pathologist at Johns Hopkins University.<ref name="pmid13426687">{{cite journal| author=RICH AR| title=A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. | journal=Bull Johns Hopkins Hosp | year= 1957 | volume= 100 | issue= 4 | pages= 173-86 | pmid=13426687 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13426687  }} </ref>
*In 1970, Jacob Churg and colleagues finally classified FSGS as a unique renal glomerulopathy in the " Pathology of the Nephrotic Syndrome in Children: Report for the International International Study of Kidney Disease in Children" in view of its clinical and pathological features, and its steroid-resistance in comparison to minimal change disease.<ref name="pmid4193942">{{cite journal| author=Churg J, Habib R, White RH| title=Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. | journal=Lancet | year= 1970 | volume= 760 | issue= 1 | pages= 1299-302 | pmid=4193942 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4193942  }} </ref>
*In 1970, Jacob Churg and colleagues finally classified FSGS as a unique renal glomerulopathy in the " Pathology of the Nephrotic Syndrome in Children: Report for the International International Study of Kidney Disease in Children" in view of its clinical and pathological features, and its steroid-resistance in comparison to minimal change disease.<ref name="pmid4193942">{{cite journal| author=Churg J, Habib R, White RH| title=Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. | journal=Lancet | year= 1970 | volume= 760 | issue= 1 | pages= 1299-302 | pmid=4193942 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4193942  }} </ref>
*The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].





Revision as of 14:10, 29 June 2018

Focal segmental glomerulosclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Focal segmental glomerulosclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Focal segmental glomerulosclerosis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Focal segmental glomerulosclerosis historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Focal segmental glomerulosclerosis historical perspective

CDC on Focal segmental glomerulosclerosis historical perspective

Focal segmental glomerulosclerosis historical perspective in the news

Blogs on Focal segmental glomerulosclerosis historical perspective

Directions to Hospitals Treating Focal segmental glomerulosclerosis

Risk calculators and risk factors for Focal segmental glomerulosclerosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [3] Olufunmilola Olubukola M.D.[4]

Overview

Historical Perspective

Discovery

  • Focal segmental glomerulosclerosis (FSGS) was first discovered by a Theodor Fahr, a German pathologist, in 1925, he referred to it as "lipoid nephrosis with degeneration", showing a clear association to minimal change disease.[1]
  • In 1957, FSGS was then described by Dr. Arnold Rich, a pathologist at Johns Hopkins University.[2]
  • In 1970, Jacob Churg and colleagues finally classified FSGS as a unique renal glomerulopathy in the " Pathology of the Nephrotic Syndrome in Children: Report for the International International Study of Kidney Disease in Children" in view of its clinical and pathological features, and its steroid-resistance in comparison to minimal change disease.[3]


References

  1. Fahr, T (1925). Pathologische anatomie des morbus brightii. In: Fahr T, Gruber GB, Koch M, et al. eds. Harnorgane Männliche Geschlechtsorgane. Vienna: Springer. pp. 156–472.
  2. RICH AR (1957). "A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis". Bull Johns Hopkins Hosp. 100 (4): 173–86. PMID 13426687.
  3. Churg J, Habib R, White RH (1970). "Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children". Lancet. 760 (1): 1299–302. PMID 4193942.

Template:WH Template:WS